CL2011003043A1 - Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue. - Google Patents
Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.Info
- Publication number
- CL2011003043A1 CL2011003043A1 CL2011003043A CL2011003043A CL2011003043A1 CL 2011003043 A1 CL2011003043 A1 CL 2011003043A1 CL 2011003043 A CL2011003043 A CL 2011003043A CL 2011003043 A CL2011003043 A CL 2011003043A CL 2011003043 A1 CL2011003043 A1 CL 2011003043A1
- Authority
- CL
- Chile
- Prior art keywords
- dengue virus
- composition
- vaccine
- dengue
- vaccine composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composición para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composición de vacuna del dengue; kit de vacuna porque comprende al menos una composición de vacuna contra el virus del dengue.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18302009P | 2009-06-01 | 2009-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2011003043A1 true CL2011003043A1 (es) | 2012-07-20 |
Family
ID=43220488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2011003043A CL2011003043A1 (es) | 2009-06-01 | 2011-12-01 | Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue. |
Country Status (17)
Country | Link |
---|---|
US (2) | US9211323B2 (es) |
EP (1) | EP2438198A4 (es) |
JP (2) | JP5848243B2 (es) |
KR (1) | KR101876304B1 (es) |
CN (2) | CN102449172A (es) |
AU (3) | AU2010256845B2 (es) |
CA (1) | CA2763944A1 (es) |
CL (1) | CL2011003043A1 (es) |
CO (1) | CO6470882A2 (es) |
CU (1) | CU20110219A7 (es) |
IL (2) | IL216706A0 (es) |
MX (1) | MX343172B (es) |
MY (1) | MY184428A (es) |
NZ (2) | NZ597000A (es) |
PH (1) | PH12016502431A1 (es) |
SG (1) | SG176299A1 (es) |
WO (1) | WO2010141386A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
AU2010256845B2 (en) * | 2009-06-01 | 2016-09-22 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
EP2858668A1 (en) * | 2012-06-10 | 2015-04-15 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
JP2016504315A (ja) * | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
CN105451763B (zh) | 2013-03-15 | 2021-06-18 | 武田疫苗股份有限公司 | 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法 |
EP3442571A1 (en) | 2016-04-13 | 2019-02-20 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
AU2018388102A1 (en) | 2017-12-21 | 2020-07-16 | Green Biomed, Inc. | Cross-immunizing antigen vaccine and method for preparation thereof |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
CA3111332A1 (en) | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2153223T3 (es) * | 1991-09-19 | 2001-02-16 | Us Health | Flavivirus quimericos y/o flavivirus de crecimiento restringido. |
FR2741077B1 (fr) * | 1995-11-14 | 1998-01-23 | Pasteur Institut | Vaccin polyvalent anti-dengue |
WO2000057907A2 (en) * | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Multivalent dengue virus vaccine |
AU3844101A (en) * | 2000-02-16 | 2001-08-27 | Us Health | Avirulent, immunogenic flavivirus chimeras |
EP1159969A1 (fr) * | 2000-05-30 | 2001-12-05 | Aventis Pasteur | Vaccine composition |
CA3114957C (en) | 2001-05-22 | 2022-02-08 | Stephen S. Whitehead | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
US20040120964A1 (en) * | 2001-10-29 | 2004-06-24 | Mikszta John A. | Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses |
WO2003101397A2 (en) * | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
CA2584228C (en) * | 2004-10-20 | 2015-05-05 | Acambis Inc. | Vaccines against japanese encephalitis virus and west nile virus |
US8110196B2 (en) | 2005-04-29 | 2012-02-07 | Polytopas LLC | Methods and compositions for polytopic vaccination |
US7618393B2 (en) * | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
KR101582163B1 (ko) * | 2005-06-17 | 2016-01-05 | 사노피 파스퇴르 | 약독화된 뎅기 혈청형 2 균주 |
US20080193477A1 (en) | 2005-08-10 | 2008-08-14 | Acambis Inc. | Vaccination Against Dengue Virus Infection |
CN101287490B (zh) * | 2005-08-10 | 2013-04-24 | 阿坎姆比斯公司 | 对抗登革热病毒感染的疫苗接种 |
DK2589602T3 (en) * | 2006-08-15 | 2016-07-25 | The Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of | Development of dengue virus vaccine components |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
WO2008085288A1 (en) * | 2007-01-11 | 2008-07-17 | Sealed Air Corporation (Us) | Method of shaping insulation |
WO2008157136A1 (en) | 2007-06-14 | 2008-12-24 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Chimeric sle/dengue type 4 antigenic viruses |
AU2010256845B2 (en) | 2009-06-01 | 2016-09-22 | Takeda Vaccines, Inc. | Compositions and methods for administration of vaccines against dengue virus |
US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
-
2010
- 2010-05-28 AU AU2010256845A patent/AU2010256845B2/en not_active Ceased
- 2010-05-28 CN CN2010800241489A patent/CN102449172A/zh active Pending
- 2010-05-28 MY MYPI2011005768A patent/MY184428A/en unknown
- 2010-05-28 NZ NZ597000A patent/NZ597000A/en not_active IP Right Cessation
- 2010-05-28 CA CA2763944A patent/CA2763944A1/en not_active Abandoned
- 2010-05-28 KR KR1020117031022A patent/KR101876304B1/ko active IP Right Grant
- 2010-05-28 SG SG2011088788A patent/SG176299A1/en unknown
- 2010-05-28 CN CN201711026301.1A patent/CN107913406A/zh active Pending
- 2010-05-28 WO PCT/US2010/036726 patent/WO2010141386A1/en active Application Filing
- 2010-05-28 MX MX2011012807A patent/MX343172B/es active IP Right Grant
- 2010-05-28 JP JP2012513332A patent/JP5848243B2/ja not_active Expired - Fee Related
- 2010-05-28 EP EP10783881.5A patent/EP2438198A4/en not_active Withdrawn
- 2010-05-28 NZ NZ618158A patent/NZ618158A/en not_active IP Right Cessation
- 2010-05-28 US US12/790,511 patent/US9211323B2/en not_active Expired - Fee Related
-
2011
- 2011-11-29 CU CU20110219A patent/CU20110219A7/es unknown
- 2011-11-30 IL IL216706A patent/IL216706A0/en not_active IP Right Cessation
- 2011-12-01 CL CL2011003043A patent/CL2011003043A1/es unknown
- 2011-12-12 CO CO11170641A patent/CO6470882A2/es not_active Application Discontinuation
-
2015
- 2015-11-06 US US14/935,281 patent/US10010600B2/en not_active Expired - Fee Related
- 2015-11-26 JP JP2015230723A patent/JP2016033151A/ja active Pending
- 2015-12-17 IL IL243204A patent/IL243204A0/en unknown
-
2016
- 2016-12-05 PH PH12016502431A patent/PH12016502431A1/en unknown
- 2016-12-22 AU AU2016277660A patent/AU2016277660A1/en not_active Abandoned
-
2019
- 2019-01-11 AU AU2019200212A patent/AU2019200212A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL216706A0 (en) | 2012-02-29 |
US20160129102A1 (en) | 2016-05-12 |
JP5848243B2 (ja) | 2016-01-27 |
NZ597000A (en) | 2014-07-25 |
CO6470882A2 (es) | 2012-06-29 |
US9211323B2 (en) | 2015-12-15 |
JP2012528794A (ja) | 2012-11-15 |
MY184428A (en) | 2021-04-01 |
EP2438198A4 (en) | 2014-05-14 |
CA2763944A1 (en) | 2010-12-09 |
JP2016033151A (ja) | 2016-03-10 |
AU2010256845A1 (en) | 2011-12-22 |
CN102449172A (zh) | 2012-05-09 |
SG176299A1 (en) | 2012-01-30 |
AU2019200212A1 (en) | 2019-01-31 |
AU2016277660A1 (en) | 2017-01-12 |
PH12016502431A1 (en) | 2019-02-11 |
KR101876304B1 (ko) | 2018-07-10 |
NZ618158A (en) | 2015-05-29 |
MX343172B (es) | 2016-10-26 |
CN107913406A (zh) | 2018-04-17 |
IL243204A0 (en) | 2016-02-29 |
WO2010141386A1 (en) | 2010-12-09 |
MX2011012807A (es) | 2012-01-30 |
US20100303860A1 (en) | 2010-12-02 |
CU20110219A7 (es) | 2012-06-21 |
KR20120027396A (ko) | 2012-03-21 |
EP2438198A1 (en) | 2012-04-11 |
US10010600B2 (en) | 2018-07-03 |
AU2010256845B2 (en) | 2016-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2011003043A1 (es) | Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue. | |
CL2016001580A1 (es) | Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación. | |
CL2012000573A1 (es) | Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv. | |
CL2012001176A1 (es) | Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv. | |
CL2012002489A1 (es) | Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c. | |
CL2011000558A1 (es) | Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c. | |
CL2015000487A1 (es) | Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb). | |
CL2009002207A1 (es) | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. | |
CL2012001959A1 (es) | Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae. | |
CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
BR112012024432A2 (pt) | composição farmacêutica de dissolução rápida | |
CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
EA201071378A1 (ru) | Дронедарон для предотвращения постоянной фибрилляции предсердий | |
PH12015501637A1 (en) | Inactivated dengue virus vaccine with aluminium-free adjuvant | |
GT201500005A (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
BR112014021065A2 (pt) | Inibidor de uma interação entre fosfatidilserina e um receptor tam, composição farmacêutica e uso de um inibidor | |
BRPI0914069A2 (pt) | composição de vacina para uso contra o influenza | |
CL2013003229A1 (es) | Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc. | |
AR068565A1 (es) | Composiciones para el tratamiento del cabello | |
CL2013001877A1 (es) | Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus. | |
EA201290373A1 (ru) | Синергическая противовирусная композиция и ее применение | |
CL2014003012A1 (es) | Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c. | |
CL2016000300A1 (es) | Métodos terapéuticos |